-The Indian Express This, despite it being contract-manufactured by Pune’s Serum Institute of India whose CEO Adar Poonawalla had said that the firm was making a profit even at a price of Rs 150 per dose. At Rs 600 per dose, Indians getting inoculated with Covishield at private hospitals from May 1 could end up paying the highest price in the world for this vaccine developed by the University of Oxford and...

-The Telegraph The Centre had last November announced a Rs 900-crore project but none of this money went to either Covishield or Covaxin India’s shortage of Covid-19 vaccines that precludes immediate inoculation for all adults is rooted in the Narendra Modi government’s lack of funding for key vaccines under development and evaluation, experts have said. The experts, who have tracked global vaccine efforts, said the Indian government’s lack of investments contrasted with the...

-The Indian Express Maharashtra is staring at a shortage of both beds and vaccines. With the state estimated to record around 60,000 new cases daily for next few days, a bed shortage may just be 7-10 days away. Ahead of the Prime Minister’s meeting with Chief Ministers on managing the Covid-19 surge, a look at some states, their issues with beds and vaccines, and their demands of the Centre. Odisha Odisha only has three...

-The Hindu PM chairs meeting; number of new cases crosses 1 lakh. The Russia-made Sputnik V vaccine may be cleared for emergency use in India within 10 days, a highly placed official confirmed to The Hindu on condition of anonymity. The possible approval for a third vaccine candidate comes as Prime Minister Narendra Modi chaired a high-level meeting on Sunday to review the situation and the on-going vaccination programme with the number of...

-The Hindu Haryana, Gujarat, Madhya Pradesh, Punjab and Maharashtra are the top States registering a rise in the number of COVID cases India’s indigenous COVID-19 vaccine Covaxin from Hyderabad-based Bharat Biotechis now authorised for emergency use on a par with Oxford-AstraZeneca’s Covishield, NITI Aayog’s member (health) V.K. Paul said on Thursday. India is now seeing a rise in the number of active cases after touching lowest mark in mid-February. Haryana, Gujarat, Madhya Pradesh,...